SHANGHAI HEARTCARE MEDICAL TECHNOLOGY CORPORATION LIMITED

Ratings Shanghai HeartCare Medical Technology Corporation Limited

Equities

6609

CNE100004MN5

Delayed Hong Kong S.E. Other stock markets 04:08:17 2024-05-07 EDT			5-day change	1st Jan Change
19.12 ^HKD	-0.31%		+6.82%	-35.73%

03-28	Shanghai HeartCare Medical Technology Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Shanghai HeartCare Offloads Stake in Medical Device Developer Shenji Medical	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The stock, which is currently worth 2024 to 0.75 times its sales, is clearly overvalued in comparison with peers.
The company's share price in relation to its net book value makes it look relatively cheap.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 956 times its estimated earnings per share for the ongoing year.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SHANGHAI HEARTCARE MEDICAL TECHNOLOGY CORPORATION LIMITED	-35.73%	93.24M	-
ABBOTT LABORATORIES	-3.54%	185B	C+
MEDTRONIC PLC	-0.58%	109B	C
BECTON, DICKINSON AND COMPANY	-2.74%	68.54B	A
DEXCOM, INC.	+4.84%	51.74B	B-
CENCORA, INC.	+10.40%	45.22B	B-
HOYA CORPORATION	+3.12%	41.74B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+2.87%	26.69B	B
WEST PHARMACEUTICAL SERVICES, INC.	+4.61%	26.83B	A-
TERUMO CORPORATION	+11.62%	25.63B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes